2. Apoptosis NF-κB Immunology/Inflammation Metabolic Enzyme/Protease
  3. Apoptosis NF-κB Reactive Oxygen Species (ROS)
  4. CIGB-552

CIGB-552 是一种具有抗肿瘤特性的细胞穿透肽，在 H460 细胞中的 IC50 为 23 μM。CIGB-552 可以增加 COMMD1 蛋白的水平。CIGB-552 显著抑制 NF-κB 信号通路。CIGB-552 可以促进肿瘤细胞的凋亡 (apoptosis)。CIGB-552 可以诱导肿瘤细胞中活性氧 (ROS) 的积累。CIGB-552 具有抗炎和抗血管生成作用。CIGB-552 可用于肺癌和结肠癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

CIGB-552

CIGB-552 Chemical Structure

CAS No. : 1630763-23-3

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

CIGB-552 相关抗体

Top Publications Citing Use of Products

查看 NF-κB 亚型特异性产品:

查看所有亚型
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

CIGB-552 is a cell-penetrating peptide with anti-tumor properties with the IC50 of 23 μM in H460 cells. CIGB-552 can increase the level of protein COMMD1. CIGB-552 significantly inhibits the NF-κB signaling pathway. CIGB-552 can promote apoptosis of the tumor cells. CIGB-552 can induce the accumulation of reactive oxygen species (ROS) in tumor cells. CIGB-552 has anti-inflammatory and anti-angiogenic effects. CIGB-552 can be used for the research of the lung cancer and colon cancer[1][2][3][4].

体外研究
(In Vitro)

CIGB-552 (20-60 μM，5 小时) 可以增加抗肿瘤相关蛋白 COMMD1 的蛋白质含量[1]。

CIGB-552 (25 μM，0-12 小时) 促进 RelA 的泛素化降解并抑制 H460 细胞中 NF-κB 信号传导[1]。

CIGB-552 (25 μM，0-24 小时) 可提高 H460 细胞中促凋亡蛋白的水平，降低抗凋亡蛋白的含量[1]。

CIGB-552 (25 μM，24-48 小时) 可诱导肺癌细胞凋亡[1]。

CIGB-552 (25 μM，8 小时) 会降低 H460 细胞抗氧化能力，导致蛋白质和脂质氧化损伤[1]。

CIGB-552 (37.5 μM，1 小时) 通过抑制 SOD1 活性诱导活性氧 (ROS) 的积累，选择性杀死肿瘤细胞[2]。

CIGB-552 (75-150 μM，24 小时) 可以显著抑制 TNF-α 诱导的 NF-κB 活化[3]。

CIGB-552 (2.5-25 μM，24 小时) 通过 COMMD1 抑制缺氧诱导的 HIF-1 激活，从而发挥抗血管生成作用[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CIGB-552 相关抗体:

Cell Viability Assay[1]

Cell Line: H460, H-125, H-82, LS174T, MDA-231 and PBMC cells
Concentration: 0-200 μM
Incubation Time: 48 h
Result: Had better cytotoxicity against H460 (IC50 = 23 μM, H-125 (IC50 = 42 μM), H-82 (IC50 = 15 μM), LS174T (IC50 = 22 μM), MDA-231 (IC50 = 40 μM) and PBMC (IC50 = 249 μM) cells compared to the control group.

Western Blot Analysis[1]

Cell Line: H460, MCF7, and HT29 cells
Concentration: 20-60 μM, MG132 (HY-13259) as a control group
Incubation Time: 5 h
Result: Increased the protein level of COMMD1 in three types of cancer cells.

Western Blot Analysis[1]

Cell Line: H460 cells
Concentration: 25 μM
Incubation Time: 24 h
Result: Increased the level of protein Bax, decreased the amount of protein Bcl-2, and activated Caspase-3 and PARP cleavage.

Apoptosis Analysis[1]

Cell Line: H460 cells
Concentration: 25 μM
Incubation Time: 24-48 h
Result: Significantly increased the apoptosis rate of cells compared to the control group
药代动力学
(Parmacokinetics)[4]
Species Dose Route Indicator value
Mice 5 ug s.c. Tmax 0.33 h
Mice 5 ug s.c. AUC0-∞ 161.30 ng·h/mL
Mice 5 ug s.c. Vd/F 362.29 mL
Mice 5 ug s.c. MRT 7 h
Mice 5 ug s.c. T1/2 8.10 h
Mice 5 ug s.c. Cmax 82.2 ng/mL
体内研究
(In Vivo)

CIGB-552 (1 mg/kg；皮下注射；每周三次；持续三周) 显著抑制肺癌小鼠的肿瘤生长，延长存活时间，但不会造成显著毒性[2]。
CIGB-552 (0.2-1.4 mg/kg；皮下注射；每周两次；持续两周) 显著抑制结肠癌小鼠的肿瘤生长，并具有抗血管生成作用[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 5×104 TC-1 cells injected the C57/BL6 female mice (8 weeks, 18-20g)[2]
Dosage: 1 mg/kg, combination with 0.4 mg/kg Cisplatin (HY-17394)
Administration: Subcutaneous injection (s.c.); three times a week for three weeks
Result: Significantly reduced tumor volume of the cancer mice.
Improved the survival rate of the cancer mice.
Animal Model: 7×104 CT-26 cells injected the BALB/c mice[4]
Dosage: 0.2 or 0.7 mg/kg
Administration: Subcutaneous injection (s.c.); two times a week for two weeks
Result: Inhibited the tumor volume of tumor mice and caused apoptosis of cells at the tumor site.
Animal Model: 1×107 HT-29 cells injected the female athymic nu/nu(nude) mice[4]
Dosage: 0.7 or 1.4 mg/kg
Administration: Subcutaneous injection (s.c.); two times a week for two weeks
Result: Inhibited the tumor volume of tumor mice and reduced tumor microvascular density.
分子量

2689.21

Formula

C131H198N38O24
CAS 号
Sequence

Ac-His-Ala-Arg-Ile-Lys-{d-Pro}-Thr-Phe-Arg-Arg-{d-Leu}-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe-Trp
Sequence Shortening

Ac-HARIK-{d-Pro}-TFRR-{d-Leu}-KWKYKGKFW
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

CIGB-552 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CIGB-5521630763-23-3CIGB552CIGB 552ApoptosisNF-κBReactive Oxygen Species (ROS)Nuclear factor-κBNuclear factor-kappaBantitumorCOMMD1NFκBHIFlung cancercolon cancerinflammationInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
CIGB-552
目录号：
HY-P11115
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z